Virios Therapeutics Shares Tank After Failing Fibromyalgia Study
Virios Therapeutics Inc’s (NASDAQ:VIRI) shares crashed after its FORTRESS Phase 2b trial of IMC-1 antiviral combination therapy for fibromyalgia failed…
NeuroSense Announces The Peer-Reviewed Publication Of PrimeC Phase IIa ALS Study In Amyotrophic Lateral Sclerosis And Frontotemporal Degeneration
CAMBRIDGE, Mass., Sept. 19, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the
Shockwave Medical Initiates All-Female Coronary Intravascular Lithotripsy Study To Treat Severely Calcified Cardiovascular Disease
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions
Study Seeks to Confirm Benefits of Shockwave's Coronary IVL in Females Who Historically Have Suffered Less
Abiomed Highlights Multi-Society Study Of Impella-supported Patients
Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The
Gain Therapeutics Highlights Presentation Of Preclinical Data Demonstrating Potential Disease Modifying Benefits Of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 In Two Preclinical Models Of Parkinson’s Disease
Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills
Results Presented at the International Congress of Parkinson's Disease and
Inari Medical Announces Results From The Fully Enrolled 800-patient US Cohort Of The FlowTriever FLASH Registry
Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive
Teva To Start Nationwide Settlement Of Opioid Lawsuits From Next Year: Report
Reuters reported that Teva Pharmaceutical Industries Ltd’s (NYSE:TEVA) CEO said the company will finalize the U.S. opioid settlement by the end…
Valneva Cuts Ties With Its COVID-19 Vaccine Manufacturing Partner In Germany
Valneva SE (NASDAQ:VALN) and IDT Biologika will terminate their collaboration following the delivery of inactivated COVID-19 bulk vaccine to Valneva and…
PolyPid Announces Peer-Reviewed Publication Of Phase 2 Clinical Trial Results For D-PLEX₁₀₀ In The Prevention Of Surgical Site Infections In Abdominal Surgery
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the peer-reviewed publication of positive clinical
Sage Therapeutics And Biogen Present New Analyses At Psych Congress Further Evaluating The Efficacy And Safety Of Zuranolone
Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical